INCY vs. HOLX

In the year-to-date period, INCY achieves a 1.58% return, which is significantly higher than HOLX's -10.94% return. Over the past 10 years, INCY has underperformed HOLX with an annualized return of -1.61%, while HOLX has yielded a comparatively higher 7.32% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Incyte Corporation (INCY) and Hologic, Inc. (HOLX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current INCY Sharpe Ratio is 0.61, which is higher than the HOLX Sharpe Ratio of -0.64. The chart below compares the historical Sharpe Ratios of INCY and HOLX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither INCY nor HOLX has paid dividends to shareholders.

The maximum INCY drawdown since its inception was -98.54%, which is greater than HOLX's maximum drawdown of -93.75%. Use the drawdown chart below to compare losses from any high point for INCY and HOLX. For additional features, visit the drawdowns tool.

The current volatility for Incyte Corporation (INCY) is 10.75%, while Hologic, Inc. (HOLX) has a volatility of 11.83%. This indicates that INCY experiences smaller price fluctuations and is considered to be less risky than HOLX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Incyte Corporation and Hologic, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.